tert-butyl(2-bromoethyl)carbamate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl(2-bromoethyl)carbamate
• 英文别名: 2-Bromoethyl(tert-butyl)carbamic acid
• 化学式: C₇H₁₄BrNO₂
• 分子量: 224.098
• InChiKey: KLLARDNTHAZVKO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  tert-butyl(2-bromoethyl)carbamate 生成 tert-butyl(2-((diethoxyphosphoryl)thio) ethyl) carbamate
  参考文献：
  名称：

  Acyclic Thiol Prodrugs

  摘要：

  Disclosed herein are acyclic thiol prodrugs, and pharmaceutical compositions thereof. The prodrugs and pharmaceutical compositions thereof may be used to treat or prevent medical disorders such as, for example cystinosis, cystinuria, cancer neurodegenerative disease, Parkinson's disease, Huntington's disease, malaria, nonalcoholic fatty liver disease, radiation poisoning, arsenic poisoning, radioprotection, Wilson's disease or rheumatoid arthritis.

  公开号：

  US20230212200A1

文献信息

• Substituted Indole Compounds
  申请人：Schunk Stefan

  公开号：US20100222324A1

  公开（公告）日：2010-09-02

  Substituted indole compounds corresponding to the formula I: In which R 8 , R 9a , R 9b , R 10 , R 11 , R 200 , R 210 , A, D, T, q, s and t have defined meanings, processes for the preparation thereof, pharmaceutical compositions containing such compounds and the use of substituted indole compounds for the treatment or inhibition of pain and other conditions which are at least partly mediated by Bradykinin 1 receptors (B1R).

  将与下式I对应的吲哚化合物替代： 其中R8、R9a、R9b、R10、R11、R200、R210、A、D、T、q、s和t具有定义的含义，其制备方法，含有这种化合物的药物组合物以及用于治疗或抑制至少部分由Bradykinin 1受体（B1R）介导的疼痛和其他病症的替代吲哚化合物的用途。
• HETEROCYCLIC COMPOUND
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20160159773A1

  公开（公告）日：2016-06-09

  The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种用于预防或治疗自身免疫性疾病（例如牛皮癣、类风湿关节炎、炎症性肠病、干燥综合征、贝赫切特病、多发性硬化症、系统性红斑狼疮等）等的药剂，其具有优越的Tyk2抑制作用。 本发明涉及一种由下式表示的化合物 其中每个符号如规范中定义的，或其盐。
• MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
  申请人：AULAKH Virender Singh

  公开号：US20150266867A1

  公开（公告）日：2015-09-24

  This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.

  这项发明通常涉及公式I的抗菌化合物，如本文进一步描述，并其药用盐和制剂。在某些方面，该发明涉及使用这些化合物治疗由革兰氏阴性细菌引起的感染的方法。
• [EN] NOVEL ETHER LINKED COMPOUNDS AND IMPROVED TREATMENTS FOR CARDIAC AND CARDIOVASCULAR DISEASE<br/>[FR] NOUVEAUX COMPOSÉS À LIAISON ÉTHER ET TRAITEMENTS AMÉLIORÉS POUR LA MALADIE CARDIAQUE ET CARDIOVASCULAIRE
  申请人：UNIV NOTTINGHAM

  公开号：WO2012104659A1

  公开（公告）日：2012-08-09

  A compound of Formula (I), and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: wherein R1 is independently selected from F, CI, Br, CN, NH2, OH, CHO, COOH, oxo, C1-4alkyl, C1-4alkoxy, CONH2 (optionally mono- or di-substituted by C1-4alkyl) and SO2NH2, R2 is independently selected from C1-6allkyl substituted by R3 wherein the C1-6alkyl chain optionally comprises one or two heteroatoms select from O; R3 is selected from aryl, C3-6cycloalkyl, C3-6heterocyclyl and C3-6heteroaryl, wherein the heterocyclyl and heteroaryl rings are nitrogen containing; and wherein R3 is optonally substituted by one or more groups selected from R1; n1 is zero or an integer from 1 to 2; n2 is an integer from 1 to 2; and the sum of n1 and 2 is less than or equal to 2; R5 is selected from any group defined for R1 and R2; R6a and R6b are independently selected from H or C1-4alkyl; R7 is independently selected from F, CI, Br, CN, NH2, OH, CHO, COOH, oxo, C1-4alkyl, C1-4alkoxy, CONH2 (optionally mono- or di-substituted by C1-4alkyl) and SO2NH2, Q1, Q2 and Q3 are independently selected from H or any group defined for R1 and R2; or Q1 and Q2 or Q2 and Q3 together form a C5-6heteroaryl or C5-6heterocylclic ring; optionally containing one or two heteroatoms selected from N and O optionally substituted by any group selected from R5; Z is selected from linear C2-3 alkylene; X3 is O; X4 is selected from aryl, a 9-10 membered heteroaryl ring or a 9-10 membered heterocyclic ring, wherein the heteroaryl and heterocyclic rings contain one or more heteroatoms selected from N, and optionally additionally O, and wherein X4 is optionally substituted by one or two oxo moieties and is optionally substituted by one or more groups selected from R7; with the proviso that: (i) when X4 is phenyl then Q1 and Q2 or Q2 and Q3-together form an optionally substituted heteroaryl or heterocylclic ring as defined above; and (ii) when Q1, Q2 and Q3 are independently selected from H or any group defined for R1 and R2 then X4 is not phenyl except when R2 is C1-5alkyl substituted by R3 wherein R3 is C3-6heterocyclyl as defined above.

  公式（I）的化合物及其在自由形式或盐形式中的药学上可接受的盐或可生理水解的衍生物：其中R1独立选择自F、Cl、Br、CN、NH2、OH、CHO、COOH、oxo、C1-4烷基、C1-4烷氧基、CONH2（可选地经C1-4烷基单取代或双取代）和SO2NH2，R2独立选择自由R3取代的C1-6烷基，其中C1-6烷基链可选地包括从O中选择的一个或两个杂原子；R3选择自芳基、C3-6环烷基、C3-6杂环烷基和C3-6杂芳基，其中杂环烷基和杂芳基环含氮；其中R3可选地由R1中选择的一个或多个基团取代；n1为零或1至2的整数；n2为1至2的整数；n1和2的和小于或等于2；R5选择自定义为R1和R2的任何基团；R6a和R6b独立选择自H或C1-4烷基；R7独立选择自F、Cl、Br、CN、NH2、OH、CHO、COOH、oxo、C1-4烷基、C1-4烷氧基、CONH2（可选地经C1-4烷基单取代或双取代）和SO2NH2，Q1、Q2和Q3独立选择自H或自定义为R1和R2的任何基团；或Q1和Q2或Q2和Q3一起形成C5-6杂芳基或C5-6杂环状环；可选地含有从N和O中选择的一个或两个杂原子，可选地由R5中选择的任何基团取代；Z选择自线性C2-3烷基；X3为O；X4选择自芳基、9-10成员杂芳基环或9-10成员杂环状环，其中杂芳基和杂环状环含有从N中选择的一个或多个杂原子，可选地另外含有O，X4可选地由一个或两个oxo基团取代，并可选地由R7中选择的一个或多个基团取代；但条件是：（i）当X4为苯基时，Q1和Q2或Q2和Q3一起形成如上定义的可选取代的杂芳基或杂环状环；和（ii）当Q1、Q2和Q3独立选择自H或自定义为R1和R2的任何基团时，X4不是苯基，除非R2为由R3取代的C1-5烷基，其中R3如上所定义为C3-6杂环烷基。
• Amidinophenylpyruvic acid derivatives
  申请人：AJINOMOTO CO. INC

  公开号：US20030109547A1

  公开（公告）日：2003-06-12

  An amidinophenylpyruvic acid derivative of the following formula, analogs thereof and pharmaceutically acceptable salts thereof have an excellent antagonistic effect against activated blood coagulation factor VII. 1

  以下是该公式的一种氨基苯丙酸衍生物，其类似物和药学上可接受的盐具有出色的对激活的凝血因子VII的拮抗作用。